Related Experiment Video
Updated: Jul 14, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Abstract:
Rimonabant (Acomplia - Sanofi-Aventis) has been licensed in the UK since June 2006 for the treatment of obese and certain overweight adults. Advertisements claim the drug has beneficial effects on "cardiometabolic risk factors", and that "an estimated 50% of the effects. . .on cardiometabolic risk factors are beyond those expected from weight loss alone". Here we review the role of rimonabant in managing patients with obesity.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Drug Dosing: Obese Patients
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
The Placebo Effect
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

